Slingshot members are tracking this event:

Pfizer (PFE) Presents Phase 3b/4 ORAL Strategy Data Evaluating XELJANZ + Methotrexate (MTX) Compared to AbbVie's (ABBV) Humira in Moderate-to-Severe Rheumatoid Arthritis (RA)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 16, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3b/4, Oral Strategy, Xeljanz, Methotrexate, Humira, Moderate-to-severe Rheumatoid Arthritis